This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: May 15, 2008
Last updated: May 16, 2008
Last verified: May 2008
The purpose of the study is to determine the safety and efficacy of 5.0% and 7.5% AN2690 Solution in the treatment of distal, subungual onychomycosis of the great target toenail.

Condition Intervention Phase
Onychomycosis Drug: AN2690 Solution, 5.0% Drug: AN2690 Solution, 7.5% Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Rising Multiple-Dose, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 5.0% and 7.5% Solution for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • A calculated endpoint of treatment response at Day 180 comprised of the ISGA, clear nail growth and fungal culture results [ Time Frame: Day 180 ]

Secondary Outcome Measures:
  • Mycological and clinical response of "complete responders", "partial responders", and "non-responder". [ Time Frame: Days 180 ]

Enrollment: 60
Study Start Date: November 2005
Study Completion Date: February 2007
Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group 1
AN2690 Solution, 5.0%
Drug: AN2690 Solution, 5.0%
Once daily application for 180 days
Experimental: Group 2
AN2690 Solution, 7.5%
Drug: AN2690 Solution, 7.5%
Once daily application for 180 days

Detailed Description:
The first group of 30 protocol-qualified subjects will be assigned to Treatment Group 1 and given 5% AN2690 Solution. Provided that there is adequate evidence of clinical safety after two weeks of dosing with 5% AN2690 Solution, a second group of 30 protocol-qualified subjects will be assigned to Treatment Group 2 and given 7.5% AN2690 Solution. A third group of 30 subjects will be enrolled and assigned the highest safe concentration of AN2690 evaluated in this study.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Witnessed, signed informed consent approved by Ethics Committee
  2. Male or female subjects of any race at least 18 years of age but not older than 65 years of age at the time of screening
  3. Subjects with a diagnosis of onychomycosis of at least one great toenail and with a positive KOH wet mount from that nail
  4. Onychomycosis involving 20-60% of the affected great toenail as determined by visual inspection after the nail has been trimmed
  5. The combined thickness of the distal nail plate and the associated hyperkeratotic nail bed <3 mm
  6. Affected great toenail to be treated is capable of re-growth as documented by history or recent observation of at least 2 mm of growth
  7. Normal or not clinically significant screening safety labs

Exclusion Criteria:

  1. Females of childbearing potential not using a highly effective method of birth control (e.g. implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices) during the study
  2. Diabetes mellitus requiring treatment other than diet and exercise
  3. Subjects with chronic moccasin type of T. pedis
  4. Subjects with a history of having failed any previous topical antifungal therapy for their onychomycosis
  5. Subjects unwilling to refrain from the use of nail cosmetics such as clear and or colored nail lacquers from the screening visit until the end of the study.
  6. Subjects that have not undergone the specified washout period(s) for the following topical preparations or subjects who require the concurrent use of any of the following topical medications:

    • Topical antifungal applied to the feet (does not include antifungals for treatment of T. pedis during the study): 4 weeks
    • Anti-inflammatories, corticosteroids, topical immunomodulators: 2 weeks
  7. Subjects that have not undergone the specified washout period(s) for the following systemic medications or subjects who require the concurrent use of any of the following systemic medications:

    • Corticosteroids (including intramuscular injections): 2 weeks
    • Antifungals for treatment of onychomycosis or any systemic antifungal with known activity against dermatophytes: 24 weeks
    • Systemic immunomodulators: 4 weeks
  8. Treatment of any type for cancer within the last 6 months
  9. History of any significant internal disease
  10. Subjects with a medical history of current or past psoriasis of the skin and/or nails
  11. Concurrent lichen planus
  12. Subjects who are known to be allergic to any of the test product(s) or any components in the test product(s) or history of hypersensitivity or allergic reactions to any of the study preparations as described in the Investigator's Brochure
  13. Nail or anatomic abnormalities of the toe, e.g., genetic nail disorders, primentary disorders, onychogryphosis, trauma to the nail(s) to be treated
  14. AIDS or AIDS related complex
  15. History of street drug or alcohol abuse
  16. Any subject not able to meet the study attendance requirements
  17. Subjects who have participated in any other trial of an investigational drug or device within 60 days prior to enrollment or participation in a research study concurrent with this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00679523

Unidad de Investigación en Salud (UIS)
Chihuahua, Mexico
Hospital "Dr. Angel Leaño"
Guadalajara, Mexico
Instituto Dermatologico Jalisciense
Guadalajara, Mexico
Centro Dermatologico Pascua
Mexico City, Mexico
CIF-BIOTEC Medica Sur.
Mexico City, Mexico
Mexico City, Mexico
Hospital Universitario Dr. José Eleuterio González
Monterrey, Mexico
MIRC / OCA Hospital
Monterrey, Mexico
Toluca, Mexico
Sponsors and Collaborators
Study Director: Karl Beutner, MD, PhD Pfizer
  More Information

Responsible Party: Karl Beutner, MD, PhD, Anacor Pharmaceuticals, Inc. Identifier: NCT00679523     History of Changes
Other Study ID Numbers: AN2690-ONYC-201 Cohort 1 & 2
Study First Received: May 15, 2008
Last Updated: May 16, 2008

Keywords provided by Pfizer:
Fungal Nail

Additional relevant MeSH terms:
Skin Diseases, Infectious
Nail Diseases
Skin Diseases
Pharmaceutical Solutions
Antifungal Agents
Anti-Infective Agents processed this record on August 18, 2017